Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!

Not Yet Recruiting

A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult Participants - IM011-113

Updated: 7 August, 2020   |   ClinicalTrials.gov

Print Friendly Summary

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.
Print this page IM011-113
Download Study Participant’s Guide

SELECT LANGUAGE

Trial Details

  • Phase 1

    Phase

  • Gender(s)

  • 18-55

    Age Range

  • Not Yet Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: Treatment Group 1
Drug: BMS-986165 Tablet formulation 2 Drug: BMS-986165 Tablet formulation 1
Experimental: Treatment Group 10
Drug: BMS-986165 Tablet formulation 2 Drug: BMS-986165 Tablet formulation 1
Experimental: Treatment Group 2
Drug: BMS-986165 Tablet formulation 2 Drug: BMS-986165 Tablet formulation 1
Experimental: Treatment Group 3
Drug: BMS-986165 Tablet formulation 1 Drug: BMS-986165 Tablet formulation 2
Experimental: Treatment Group 4
Drug: BMS-986165 Tablet formulation 2 Drug: BMS-986165 Tablet formulation 1
Experimental: Treatment Group 5
Drug: BMS-986165 Tablet formulation 2 Drug: BMS-986165 Tablet formulation 1
Experimental: Treatment Group 6
Drug: BMS-986165 Tablet formulation 2 Drug: BMS-986165 Tablet formulation 1
Experimental: Treatment Group 7
Drug: BMS-986165 Tablet formulation 1 Drug: BMS-986165 Tablet formulation 2
Experimental: Treatment Group 8
Drug: BMS-986165 Tablet formulation 1 Drug: BMS-986165 Tablet formulation 2
Experimental: Treatment Group 9
Drug: BMS-986165 Tablet formulation 1 Drug: BMS-986165 Tablet formulation 2

Key Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Healthy participants, as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations in the opinion of the investigator - Women and men must agree to follow specific methods of contraception, if applicable Exclusion Criteria: - Any significant acute or chronic medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study, including a history of/or active liver disease - Inability to tolerate oral medication - History of allergy to BMS-986165 or related compounds Other protocol-defined inclusion/exclusion criteria apply

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Email Us

Have questions?
Email Us